This report, and our findings, imply that PARP7 and MACROD1 might work in concert to regulate ERα activity by catalyzing the transfer or removal of ADP-ribose on the receptor’s AF-1 domain and may represent novel targets for ER positive breast cancer treatment. The gene discussed is MACROD1; the disease is breast cancer.